• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.恢复期血浆，一项针对并激励新冠病毒19康复患者的单采研究项目：对捐赠者和受者都有临床益处的振奋人心的信息。
Transfus Apher Sci. 2020 Jun;59(3):102794. doi: 10.1016/j.transci.2020.102794. Epub 2020 Apr 23.
2
Treatment for emerging viruses: Convalescent plasma and COVID-19.新兴病毒的治疗：恢复期血浆与新冠肺炎
Transfus Apher Sci. 2020 Jun;59(3):102790. doi: 10.1016/j.transci.2020.102790. Epub 2020 Apr 20.
3
Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.来自新冠病毒感染康复者的捐赠者血浆——优先事项问题
Transfus Clin Biol. 2020 Aug;27(3):167-168. doi: 10.1016/j.tracli.2020.05.002. Epub 2020 Jun 12.
4
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.中国武汉 COVID-19 恢复期血浆采集试点项目的可行性。
Transfusion. 2020 Aug;60(8):1773-1777. doi: 10.1111/trf.15921. Epub 2020 Jul 31.
5
Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.COVID-19时代恢复期超免疫血浆生产面临的挑战
Semin Thromb Hemost. 2020 Oct;46(7):804-806. doi: 10.1055/s-0040-1713433. Epub 2020 Jun 8.
6
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
7
Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.关于制备用于治疗COVID-19患者的免疫血浆的立场文件。
Transfus Apher Sci. 2020 Aug;59(4):102817. doi: 10.1016/j.transci.2020.102817. Epub 2020 May 21.
8
Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.恢复期血浆治疗 COVID-19：2020 年 4 月 22 日至 5 月 12 日，英国与高中和抗体水平相关的因素包括男性、年龄较大和住院。
Euro Surveill. 2020 Nov;25(45). doi: 10.2807/1560-7917.ES.2020.25.45.2001754.
9
Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.COVID-19 恢复期血浆捐献者的特征和血清学模式：最佳捐献者和捐献时间。
Transfusion. 2020 Aug;60(8):1765-1772. doi: 10.1111/trf.15918. Epub 2020 Jul 6.
10
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 型感染：2020 年 4 月 22 日至 5 月 12 日期间英国前 436 位供者的分析。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2001260.

引用本文的文献

1
Convalescent plasma therapy for COVID-19 in patients with nasal catheter oxygen therapy.鼻导管吸氧的COVID-19患者的恢复期血浆治疗
J Thorac Dis. 2025 Jun 30;17(6):3532-3546. doi: 10.21037/jtd-2024-1991. Epub 2025 Jun 11.
2
The relationship between knowledge, attitude, and practice of plasma donation with age and gender as moderators: a cross-sectional survey.以年龄和性别作为调节变量的血浆捐献知识、态度和行为之间的关系：一项横断面调查
Ann Med Surg (Lond). 2023 Mar 16;85(5):1594-1600. doi: 10.1097/MS9.0000000000000121. eCollection 2023 May.
3
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.新冠疫情期间恢复期血浆疗法（CCP）的有效性：文献综述
J Blood Med. 2023 Feb 22;14:159-187. doi: 10.2147/JBM.S397722. eCollection 2023.
4
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.用于COVID-19治疗的康复期血浆（高免疫球蛋白）：最新情况
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
5
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.COVID-19 合并血液系统恶性肿瘤患者恢复期血浆治疗无效：一项意大利回顾性研究。
Hematol Oncol. 2022 Dec;40(5):857-863. doi: 10.1002/hon.3060. Epub 2022 Aug 14.
6
Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.聚焦最新观点：新型冠状病毒变异株的鉴定、预防和管理：奥密克戎的创新性思路和设计疫苗综述评价。
Transfus Apher Sci. 2022 Dec;61(6):103499. doi: 10.1016/j.transci.2022.103499. Epub 2022 Jul 3.
7
COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.COVID-19 恢复期血浆：当前状况、既往经验教训和未来展望。
Transfus Apher Sci. 2022 Aug;61(4):103487. doi: 10.1016/j.transci.2022.103487. Epub 2022 Jun 11.
8
Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.恢复期血浆疗法对中重度 COVID-19 患者死亡率的影响。
Transfus Apher Sci. 2022 Dec;61(6):103455. doi: 10.1016/j.transci.2022.103455. Epub 2022 May 11.
9
The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report.使用恢复期血浆疗法治疗 COVID-19 孕妇：病例报告。
Einstein (Sao Paulo). 2022 Feb 16;20:eRC6550. doi: 10.31744/einstein_journal/2022RC6550. eCollection 2022.
10
Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma.微流控分析揭示了人类血浆中 SARS-CoV-2 抗体的广泛亲和力。
Life Sci Alliance. 2021 Nov 30;5(2). doi: 10.26508/lsa.202101270. Print 2022 Feb.

本文引用的文献

1
Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.对最需要者的被动免疫疗法的思考：从康复的新冠病毒感染患者获取更安全的治疗性血浆或自体抗体的一些新颖策略性观点。
Br J Haematol. 2020 Jul;190(1):e27-e29. doi: 10.1111/bjh.16814. Epub 2020 Jun 9.
2
Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?新冠病毒19、诱导的止血激活和免疫反应：自身免疫反应是否会导致某些患者出现延迟性严重并发症？
Transfus Apher Sci. 2020 Jun;59(3):102804. doi: 10.1016/j.transci.2020.102804. Epub 2020 May 3.
3
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
4
How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?面对迫在眉睫的新冠疫情威胁，我们应如何规划造血细胞移植和细胞治疗？
Br J Haematol. 2020 Apr;189(2):239-240. doi: 10.1111/bjh.16597. Epub 2020 Mar 16.
5
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
6
0.9% NaCl (Normal Saline) - Perhaps not so normal after all?0.9%氯化钠溶液（生理盐水）——也许终究并非那么“生理”？
Transfus Apher Sci. 2018 Feb;57(1):127-131. doi: 10.1016/j.transci.2018.02.021. Epub 2018 Feb 21.
7
Ebola virus convalescent blood products: where we are now and where we may need to go.埃博拉病毒康复期血液制品：我们目前的状况及可能的发展方向。
Transfus Apher Sci. 2014 Oct;51(2):120-5. doi: 10.1016/j.transci.2014.10.003.

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.

作者信息

Seghatchian J, Lanza F

机构信息

International Consultancy in Strategic Advice on Safety Improvements of Blood-Derived Bioproducts and Suppliers Quality Audit / Inspection, London, UK.

Romagna Transplant Network, Hematology Unit, Ravenna-I, Italy.

出版信息

Transfus Apher Sci. 2020 Jun;59(3):102794. doi: 10.1016/j.transci.2020.102794. Epub 2020 Apr 23.

DOI:10.1016/j.transci.2020.102794
PMID:32448638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7177094/
Abstract
摘要